Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte ratio, and Lymphocyte- to-Monocyte Ratio in Extramammary Paget’s Disease: A Retrospective Study
Clinical Summary
View sourceWhat was studied
Retrospective single-centre cohort of 85 treatment-naive patients with extramammary Paget’s disease (1994–2022) assessing whether pretreatment NLR, PLR, LMR, and PNR predict disease-specific survival using ROC-derived cutoffs and survival analyses.
Key findings
There were 11 disease-specific deaths (13%). ROC cutoffs were NLR 2.54, PLR 117, LMR 3.69, and PNR 55.6; on univariate Cox, NLR ≥2.54 (HR 17.5, 95% CI 2.89–106), PLR ≥117 (HR 21.7, 1.08–436), and LMR ≤3.69 (HR 0.11, 0.03–0.41) predicted poorer DSS (all p<0.001), while PNR was borderline (p=0.052) but significant by Kaplan–Meier (p=0.048).
Study limitations
Small, single-centre retrospective study with only 11 disease-specific events, so findings relied mainly on univariate analyses and may be unstable; proposed cutoffs need external validation, and sentinel node biopsy was not routine, limiting correlation with nodal status.
Clinical implications
Pretreatment NLR ≥2.54, PLR ≥117, and LMR ≤3.69 are simple blood-based markers that may help flag higher risk of disease-specific death in EMPD and track with aggressive features; use them only as adjuncts to established clinicopathologic factors pending validation.
Related Questions
Explore related topics and deepen your understanding